ReviewInternational journal of molecular sciences2022
Next-Generation Diagnostic with CRISPR/Cas: Beyond Nucleic Acid Detection.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- RT-RPA-Assisted CRISPR/Cas12a-Based Isothermal Detection of Chikungunya Virus.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Research Progress in Applications of the CRISPR-Cas12b System in Pathogen Nucleic Acid Detection.Current issues in molecular biology · 2026Review
- Indiscriminate Trans-Cleavage Activity of CRISPR/SuCas12a2 Enables Sensitive Detection of SARS-CoV-2.ACS sensors · 2026Article
- Application of extracellular vesicles in the CRISPR-based diagnosis and treatment: possibilities and challenges.Journal of biological engineering · 2026Review
- Synergistic integration of CRISPR/Cas and nanozymes in next-generation biosensors for ultrasensitive bacterial detection.Mikrochimica acta · 2026Review
- Engineering delivery platforms for CRISPR-Cas and their applications in healthcare, agriculture and beyond.Nanoscale advances · 2026Review
- Review
- An overview of CRISPR-artificial intelligence theranostics: Current and emerging applications.Biomaterials translational · 2026Review
- Future perspectives of GMO detection in agriculture: strategies for electrochemical nucleic acid detection.Mikrochimica acta · 2025Review
- Important applications of DNA nanotechnology combined with CRISPR/Cas systems in biotechnology.RSC advances · 2025Review
- CRISPR-Cas Systems Associated with Electrolyte-Gated Graphene-Based Transistors: How They Work and How to Combine Them.Biosensors · 2024Review
- Review
- CRISPR, CAR-T, and NK: Current applications and future perspectives.Genes & diseases · 2024Review
- Blunted blades: new CRISPR-derived technologies to dissect microbial multi-drug resistance and biofilm formation.mSphere · 2024Review
- Rapid Nucleic Acid Detection ofInternational journal of molecular sciences · 2024Article
- Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine.Frontiers in genome editing · 2024Review
- CRISPR/Cas12a-Based Detection Platform for Early and Rapid Diagnosis of Scrub Typhus.Biosensors · 2023Article
- Multiplexed CRISPR-based Methods for Pathogen Nucleic Acid Detection.Current opinion in biomedical engineering · 2023Article
- Hepatitis B virus-induced hepatocellular carcinoma: a persistent global problem.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Review
- Molecular Approaches for Detection ofBiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The early management, diagnosis, and treatment of emerging and re-emerging infections and the rising burden of non-communicable diseases (NCDs) are necessary. The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas system has recently acquired popularity as a diagnostic tool due to its ability to target specific genes. It uses Cas enzymes and a guide RNA (gRNA) to cleave target DNA or RNA. The discovery of collateral cleavage in CRISPR-Cas effectors such as Cas12a and Cas13a was intensively repurposed for the development of instrument-free, sensitive, precise and rapid point-of-care diagnostics. CRISPR/Cas demonstrated proficiency in detecting non-nucleic acid targets including protein, analyte, and hormones other than nucleic acid. CRISPR/Cas effectors can provide multiple detections simultaneously. The present review highlights the technical challenges of integrating CRISPR/Cas technology into the onsite assessment of clinical and other specimens, along with current improvements in CRISPR bio-sensing for nucleic acid and non-nucleic acid targets. It also highlights the current applications of CRISPR/Cas technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.